Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia

American Journal of Cardiology

Volumn 94, Issue 4, 2004, Pages 497-500

  Sakabe, Koichi ^a   Fukuda, Nobuo ^a   Wakayama, Katsunori ^a   Nada, Teru ^a   Shinohara, Hisanori ^a   Tamura, Yoshiyuki ^a  

^a National Hospital Organization   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PLASMINOGEN ACTIVATION; PLEIOTROPY; PRIORITY JOURNAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BASILAR ARTERY; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LONG-TERM CARE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; PYRROLES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TREATMENT OUTCOME; TRIGLYCERIDES; VASODILATION;

EID: 4344627319     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.04.067     Document Type: Article

References (20)

1. Marchesi S., Lupatteli G., Siepi D., Schillaci G., Vaudo G., Roscini A.R., Sinzinger H., Mannarino E. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 36:2000;617-621
2. Sasaki S., Kuwahara N., Kunitomo K., Harada S., Yamada T., Azuma A., Takeda K., Nakagawa M. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol. 89:2002;386-389
3. Demir M., Acarturk E., Saamaz I., Cayli M., Kikinc Y. Effects of atorvastatin on lipid profile and coagulation parameters. Curr Ther Res Clin Exp. 62:2001;691-698
4. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP) a prospective, randomized, double-blind trial. Lancet. 357:2001;577-581
5. Seljeflot I., Tonstad S., Hjermann I., Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res. 105:2002;285-290
6. Lopez S., Peiretti F., Bonardo B., Juhan-Vague I., Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 152:2000;359-366
7. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193
8. Allain C.C., Poon L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem. 20:1974;470-475
9. Burstein M., Scholnick H.R. Lipoprotein-polyanion-metal interactions. Adv Lipid Res. 11:1973;67-108
10. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest. 34:1955;1346-1353
11. Sakabe K., Fukuda N., Wakayama K., Nada T., Shinohara H., Tamura Y. Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients. Circ J. 67:2003;866-870
12. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Meth Enzymol. 52:1987;302-310
13. White C.M. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol. 39:1999;111-118
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
15. Griffin B.A., Freeman D.J., Tait G.W., Thomson J., Caslake M.J., Packard C.J., Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 106:1994;241-253
16. Fukushima H., Kugiyama K., Sugiyama S., Honda O., Koide S., Nakamura S., Kawano H., Soejima H., Miyamoto S., Yoshimura M., Sakamoto T., Ogawa H. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol. 88:2001;1370-1373
17. Nishi K., Uno M., Fukuzawa K., Horiguchi H., Shinno K., Nagahiro S. Clinicopathological significance of lipid peroxidation in carotid plaques. Atherosclerosis. 160:2002;289-296
18. Hirano T., Oi K., Sakai S., Kashiwazaki K., Adachi M., Yoshino G. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage a possible role of postprandial lipemia. Atherosclerosis. 141:1998;77-85
19. Guerin M., Egger P., Le Goff W., Soudant C., Dupuis R., Chapman M.J. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J Clin Endocrinol Metab. 87:2002;4991-5000
20. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 332:1995;635-641